Medicenna Therapeutics (OTCMKTS:MDNAF) Posts Earnings Results

Medicenna Therapeutics (OTCMKTS:MDNAF) announced its earnings results on Thursday. The company reported $999.00 EPS for the quarter, Zacks reports.

Medicenna Therapeutics Stock Up 2.2%

Shares of Medicenna Therapeutics stock traded up $0.01 on Thursday, reaching $0.29. 92,467 shares of the company were exchanged, compared to its average volume of 80,259. The firm has a market cap of $26.82 million, a P/E ratio of -2.64 and a beta of 1.71. Medicenna Therapeutics has a one year low of $0.25 and a one year high of $1.43. The firm’s 50-day moving average is $0.37.

About Medicenna Therapeutics

Medicenna Therapeutics Corp. is a clinical-stage biopharmaceutical company focused on developing next-generation cytokine-based immunotherapies for cancer and central nervous system disorders. The company applies protein-engineering approaches to create engineered cytokine therapeutics designed to enhance anti-tumor activity while reducing systemic toxicity, aiming to broaden the therapeutic window for immunomodulatory agents.

Medicenna’s pipeline includes proprietary candidates such as MDNA55, an engineered interleukin-4 (IL-4) receptor-targeted fusion protein developed for intratumoral treatment of recurrent glioblastoma and other brain tumors, and MDNA11, a long-acting engineered interleukin-2 (IL-2) “superkine” intended to stimulate anti-tumor immune responses in solid tumors with an improved safety profile.